Sector News

ConvaTec owners appoint banks to explore sale – sources

October 15, 2014
Energy & Chemical Value Chain
(Reuters) – ConvaTec’s owners have appointed Morgan Stanley and Goldman Sachs to explore a sale of the medical device maker which could be worth up to $10 billion, sources familiar with the matter said.
 
Private equity firms Avista Capital Partners and Nordic Capital are preparing the groundwork for a possible sale or initial public offering (IPO) in 2015 for the Luxembourg-based company, said the sources who spoke on condition of anonymity because the process is private.
 
Mergers and acquisitions in the healthcare space have hit a record pace so far this year, in part driven by U.S. companies seeking to redomicile in countries that have a lower corporate tax rate, in a practice known as inversion.
 
Kimberley-Clark and 3M are considered likely bidders for ConvaTec, said the sources, adding that the U.S. firms’ interest was not motivated by tax inversion issues.
 
ConvaTec, Nordic Capital, 3M, Goldman Sachs and Morgan Stanley declined to comment. Kimberley Clark and Avista Capital did not immediately respond to requests for comment.
 
Reuters reported in August that some U.S. companies including diversified manufacturer 3M and medical equipment makers CareFusion Corp and C.R. Bard Inc were potentially exploring a deal, but that ConvaTec wanted to boost its value further before launching an auction or IPO.
 
CareFusion has since been swallowed by medical equipment supplier Becton Dickinson & Co for $12.2 billion, taking them out of the field.
 
Also, in recent weeks equity markets have stumbled and the market for IPOs has stalled.
 
Avista Capital Partners and Nordic Capital acquired ConvaTec from Bristol-Myers Squibb Co in 2011 for $4.1 billion. 3M and Kimberley-Clark were among the contenders for ConvaTec at the time, according to people familiar with the matter.
 
ConvaTec reported earnings before interest, tax, depreciation and amortization (EBITDA) of $502.5 million in 2013, up 15 percent year-on-year. It is hoping to exceed $600 million in EBITDA this year, sources have said.
 
The company makes wound care and ostomy care products at 11 manufacturing sites in eight countries, and sells them in more than 100 countries.
 
BY SOPHIE SASSARD AND ANJULI DAVIES (Editing by Pravin Char)

comments closed

Related News

January 19, 2025

Heraeus acquires Umicore’s platinum API business

Energy & Chemical Value Chain

Heraeus Precious Metals announced that it has acquired Umicore’s Platinum Active Pharmaceutical Ingredient (API) business outside of South America. This transaction is a unique opportunity for Heraeus to strengthen its position and product portfolio.

January 19, 2025

Celanese announces new leadership appointment to drive growth and profitability

Energy & Chemical Value Chain

Todd Elliott, a proven executive who retired from Celanese in 2020 as Senior Vice President (SVP) and head of the Acetyls business, will return to the Company as SVP to lead the Engineered Materials (EM) business, effective February 3, 2025.

January 19, 2025

Chemours announces Damián Gumpel as President of Titanium Technologies and Diane Picho as Chief Enterprise Enablement Officer

Energy & Chemical Value Chain

Damián Gumpel joins Chemours with deep chemical industry leadership experience. At the Olin Corporation, he most recently served as Vice President, Corporate Strategy, helping to define a new corporate strategy and executing a joint venture and several M&A transactions.

How can we help you?

We're easy to reach